Hallux Raises $7.1M

Laguna Hills-based Hallux, a pharmaceuticals startup developing treatments for oncychomycosis, has raised $7.1M in a Series A funding. The funding came from Deerfield Management. Hallux is developing a priiorietary terbinafine product for treating subungual oncychomycosis--better known as nail fungus. The company says its dosage and treatment form avoid issues with current, oral therapies for treating the condition. Hallux is led by Mark Taylor. More information »